FDA inspection
Eurofins PROXY Laboratories B.V.: FDA inspection ending Sep 19, 2025
FDA inspection 1282304 · Leiden
Key facts
| Inspection ID | 1282304 |
|---|---|
| Firm | Eurofins PROXY Laboratories B.V. |
| FEI number | 3004594563 |
| Address | Darwinweg 24 |
| City | Leiden |
| Fiscal year | 2025 |
| Inspection end date | Sep 19, 2025 |
| Project area | Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Blood and Blood Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products|Human Cellular, Tissue, and Gene Therapies|Vaccine, Allergenic, and Live Biotherapeutic Products |
| Product type | Biologics, Drugs |
At a glance
- 1–9 Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data